NRAS同工型5的结构表征
Structural characterization of NRAS isoform 5.
作者信息
Markowitz Joseph, Mal Tapas K, Yuan Chunhua, Courtney Nicholas B, Patel Mitra, Stiff Andrew R, Blachly James, Walker Christopher, Eisfeld Ann-Kathrin, de la Chapelle Albert, Carson William E
机构信息
Moffitt Cancer Center Department of Cutaneous Oncology, The Ohio State University, Columbus, Ohio.
The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
出版信息
Protein Sci. 2016 May;25(5):1069-74. doi: 10.1002/pro.2916. Epub 2016 Mar 24.
Abstract
It was recently discovered that the NRAS isoform 5 (20 amino acids) is expressed in melanoma and results in a more aggressive cell phenotype. This novel isoform is responsible for increased phosphorylation of downstream targets such as AKT, MEK, and ERK as well as increased cellular proliferation. This structure report describes the NMR solution structure of NRAS isoform 5 to be used as a starting point to understand its biophysical interactions. The isoform is highly flexible in aqueous solution, but forms a helix-turn-coil structure in the presence of trifluoroethanol as determined by NMR and CD spectroscopy.
摘要
最近发现NRAS亚型5（20个氨基酸）在黑色素瘤中表达，并导致更具侵袭性的细胞表型。这种新型亚型导致下游靶点如AKT、MEK和ERK的磷酸化增加以及细胞增殖增加。本结构报告描述了NRAS亚型5的核磁共振溶液结构，作为理解其生物物理相互作用的起点。该亚型在水溶液中高度灵活，但通过核磁共振和圆二色光谱法测定，在三氟乙醇存在下形成螺旋-转角-螺旋结构。
相似文献
1
Structural characterization of NRAS isoform 5.NRAS同工型5的结构表征
Protein Sci. 2016 May;25(5):1069-74. doi: 10.1002/pro.2916. Epub 2016 Mar 24.
2
Prognostic role of NRAS isoforms in Chinese melanoma patients.NRAS 异构体在中国黑色素瘤患者中的预后作用。
Melanoma Res. 2019 Jun;29(3):263-269. doi: 10.1097/CMR.0000000000000557.
3
Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.ERK1/2 和 ERK5 MAPK 通路的协同抑制可有效抑制NRAS 驱动的黑色素瘤。
J Invest Dermatol. 2020 Dec;140(12):2455-2465.e10. doi: 10.1016/j.jid.2020.03.972. Epub 2020 May 4.
4
[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].[携带BRAF或NRAS突变的原发性人类黑色素瘤基因改变的特征分析]
Magy Onkol. 2013 Jun;57(2):96-9. Epub 2013 May 20.
5
A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.全基因组 CRISPR 筛选鉴定出 FBXO42 参与了NRAS 突变型黑色素瘤对 MEK 抑制的耐药性。
Pigment Cell Melanoma Res. 2020 Mar;33(2):334-344. doi: 10.1111/pcmr.12825. Epub 2019 Oct 10.
6
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.曲美替尼与 GSK2141795 联合抑制 MEK/AKT 对转移性NRAS 突变和野生型黑色素瘤没有临床获益。
Pigment Cell Melanoma Res. 2018 Jan;31(1):110-114. doi: 10.1111/pcmr.12644. Epub 2017 Nov 2.
7
MEK inhibitors for the treatment of NRAS mutant melanoma.用于治疗NRAS突变型黑色素瘤的MEK抑制剂。
Drug Des Devel Ther. 2018 Aug 20;12:2553-2565. doi: 10.2147/DDDT.S131721. eCollection 2018.
8
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.神经母细胞瘤 RAS 病毒癌基因同源物 mRNA 经不同剪接可产生五种不同的异构体：对黑色素瘤治疗的启示。
Melanoma Res. 2019 Oct;29(5):491-500. doi: 10.1097/CMR.0000000000000623.
9
A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.野生型 Ras 同工型在突变 KRas 驱动的信号转导和转化中的需求。
Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.
10
BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.俄罗斯黑色素瘤患者的BRAF和NRAS突变：一项全国性研究的结果
Melanoma Res. 2016 Oct;26(5):442-7. doi: 10.1097/CMR.0000000000000278.
引用本文的文献
1
Structural modifications and kinetic effects of interactions with and : an comparative analysis of mutants.与……相互作用的结构修饰和动力学效应以及……：突变体的比较分析。
（由于原文中部分关键内容缺失，可能翻译得不够准确完整，你可以补充完整原文以便更精准翻译。）
Front Mol Biosci. 2024 Aug 9;11:1436976. doi: 10.3389/fmolb.2024.1436976. eCollection 2024.
2
Roles and mechanisms of aberrant alternative splicing in melanoma - implications for targeted therapy and immunotherapy resistance.异常可变剪接在黑色素瘤中的作用和机制——对靶向治疗和免疫治疗耐药性的影响
Cancer Cell Int. 2024 Mar 10;24(1):101. doi: 10.1186/s12935-024-03280-x.
3
Splice variants of RAS-translational significance.RAS 剪接变异体的翻译意义。
Cancer Metastasis Rev. 2020 Dec;39(4):1039-1049. doi: 10.1007/s10555-020-09920-8. Epub 2020 Aug 8.
4
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.神经母细胞瘤 RAS 病毒癌基因同源物 mRNA 经不同剪接可产生五种不同的异构体：对黑色素瘤治疗的启示。
Melanoma Res. 2019 Oct;29(5):491-500. doi: 10.1097/CMR.0000000000000623.
5
5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.5-芳基（色烯基亚甲基）-噻唑烷二酮：针对结直肠癌和黑色素瘤中突变致癌蛋白 K-Ras、N-Ras 和 B-Raf 的潜在新型药物。
Medicina (Kaunas). 2019 Mar 31;55(4):85. doi: 10.3390/medicina55040085.
本文引用的文献
1
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.神经母细胞瘤 RAS 病毒癌基因同源物 mRNA 经不同剪接可产生五种不同的异构体：对黑色素瘤治疗的启示。
Melanoma Res. 2019 Oct;29(5):491-500. doi: 10.1097/CMR.0000000000000623.
2
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
3
Indications and options for systemic therapy in melanoma.黑色素瘤的系统治疗的适应证和选择。
Surg Clin North Am. 2014 Oct;94(5):1049-58, viii. doi: 10.1016/j.suc.2014.07.007. Epub 2014 Aug 6.
4
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.NRAS 异构体差异影响下游通路、细胞生长和细胞转化。
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4179-84. doi: 10.1073/pnas.1401727111. Epub 2014 Feb 28.
5
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.RAF抑制剂对表达突变BRAF剪接变体的黑色素瘤的有益作用。
Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11.
6
Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.新一代选择性RAF抑制剂对突变BRAF剪接变体信号传导的抑制作用。
Pigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10.
7
PDBStat: a universal restraint converter and restraint analysis software package for protein NMR.PDBStat：一种用于蛋白质 NMR 的通用约束转换器和约束分析软件包。
J Biomol NMR. 2013 Aug;56(4):337-51. doi: 10.1007/s10858-013-9753-7. Epub 2013 Jul 30.
8
Helical ambivalency induced by point mutations.由点突变引起的螺旋矛盾性。
BMC Struct Biol. 2013 May 15;13:9. doi: 10.1186/1472-6807-13-9.
9
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.BRAF V600 突变型黑色素瘤的联合 BRAF 和 MEK 抑制治疗。
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
10
BRAFV600E: implications for carcinogenesis and molecular therapy.BRAFV600E：致癌作用和分子治疗的意义。
Mol Cancer Ther. 2011 Mar;10(3):385-94. doi: 10.1158/1535-7163.MCT-10-0799.
Zotero 插件